{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"29.7","upperLimit":"NA","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Progression free survival (PFS) of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach (i.e. time from start of lenalidomide to failure of lenalidomide and low dose dexamethasone)","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.\n\nLenalidomide: - Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;\n\n* Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;\n* Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;\n* Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;\n* Dose Level -4: Discontinue\n\nPrednisone: - Starting Dose: 100 mg PO days 1-5 every 28 days;\n\n* Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;\n* Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;\n* Dose level -3: Discontinue\n\nDexamethasone: - Starting Dose: 40 mg daily on days 1 - 4 every 28 days;\n\n* Dose level -1: 20 mg daily on days 1 - 4 every 28 days;\n* Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;\n* Dose level -2: 10 mg daily on days 1 - 4 every 28 days;\n* Dose level -3: Discontinue","id":"OG000","title":"Response Adapted Therapy"}],"paramType":"MEDIAN","populationDescription":"Number of participants who received response adaptive therapy","reportingStatus":"POSTED","timeFrame":"up to 36 months","title":"Combined Therapy - Median Progression Free Survival","type":"PRIMARY","unitOfMeasure":"months"}